Oskar Hansson
31 – 40 of 662
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease
- Contribution to journal › Scientific review
-
Mark
Primary care detection of Alzheimer's disease using a self-administered digital cognitive test and blood biomarkers
- Contribution to journal › Article
-
Mark
CSF pTDP-43 across the Alzheimer's spectrum: Links to amyloid, APOE and vasculopathy
(2025) In Neurobiology of Disease
- Contribution to journal › Article
-
Mark
Quantitation of PET spatial extent as a potential adjunct to visual interpretation of [18F]flortaucipir imaging : TAU-SPEX
- Contribution to journal › Article
-
Mark
Hemispheric asymmetry of tau pathology is related to asymmetric amyloid deposition in Alzheimer's Disease
- Contribution to journal › Article
-
Mark
Association of plasma Alzheimer's disease biomarkers with cognitive decline in cognitively unimpaired individuals
- Contribution to journal › Article
-
Mark
Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer's disease spectrum
- Contribution to journal › Article
-
Mark
Alpha-synuclein seed amplification assay longitudinal outcomes in Lewy body disease spectrum
- Contribution to journal › Article
-
Mark
Quantification of Lewy body pathology by cerebrospinal fluid endpoint dilution RT-QuIC in a neuropathological autopsy cohort of clinically heterogeneous participants
- Contribution to journal › Article
-
Mark
How can Alzheimer's disease blood-based biomarkers reach clinical practice?
- Contribution to journal › Article
